| Dr James Gilbert Breisinger, DO | |
|
1 Mellon Way, Hospitalist, Latrobe, PA 15650-1197 | |
| (724) 309-8608 | |
| Not Available |
| Full Name | Dr James Gilbert Breisinger |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 14 Years |
| Location | 1 Mellon Way, Latrobe, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811287378 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS016454 (Pennsylvania) | Secondary |
| 208M00000X | Hospitalist | OS016454 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Excela Health Westmoreland Regional Hospital | Greensburg, PA | Hospital |
| Excela Health Latrobe Hospital | Latrobe, PA | Hospital |
| Excela Health - Frick Hospital | Mount pleasant, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Excela Health Physician Practices, Inc | 6204737117 | 438 |
News Archive
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies.
During the next three years, researchers at Case Western Reserve University will team with NASA Glenn Research Center and firefighters nationally, from Cleveland to Oregon, to design and test sensors aimed at protecting firefighters from respiratory damage and illnesses.
Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.
AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.
› Verified 9 days ago
| Entity Name | Excela Health Physician Practices, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821225202 PECOS PAC ID: 6204737117 Enrollment ID: O20040322001393 |
News Archive
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies.
During the next three years, researchers at Case Western Reserve University will team with NASA Glenn Research Center and firefighters nationally, from Cleveland to Oregon, to design and test sensors aimed at protecting firefighters from respiratory damage and illnesses.
Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.
AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Gilbert Breisinger, DO 1 Mellon Way, Hospitalist, Latrobe, PA 15650-1197 Ph: (724) 309-8608 | Dr James Gilbert Breisinger, DO 1 Mellon Way, Hospitalist, Latrobe, PA 15650-1197 Ph: (724) 309-8608 |
News Archive
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies.
During the next three years, researchers at Case Western Reserve University will team with NASA Glenn Research Center and firefighters nationally, from Cleveland to Oregon, to design and test sensors aimed at protecting firefighters from respiratory damage and illnesses.
Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.
AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.
› Verified 9 days ago
David Garzarelli, Hospitalist Medicare: Medicare Enrolled Practice Location: 1 Mellon Way, Upmc St Margaret Hospital, Latrobe, PA 15650 Phone: 724-537-1801 | |
Dr. Samuel Anthony Valletta, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Mellon Way, Latrobe, PA 15650 Phone: 724-537-1207 | |
Dr. Christopher Moore, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1 Mellon Way, Latrobe, PA 15650 Phone: 724-537-1801 |